Targeted radionuclide therapy to boost CAR T cells for neuroblastoma
Official title: Targeted Radionuclide Therapy to Enhance the Efficacy of CAR T Cells Against Neuroblastoma
Funded at University of Wisconsin-Madison · NIH-11379963 · Data updated 2026-11-12
A doctor-researcher is developing a treatment that combines targeted radiation with CAR T cell therapy to improve outcomes for kids with neuroblastoma.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $159,636 |
| NIH project number | 5K08CA285941-03 |
| Project ID | NIH-11379963 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are pediatric patients with neuroblastoma or related solid tumors who may benefit from enhanced CAR T cell therapy.
✕Less likely to help
Patients whose tumors do not respond to CAR T cell therapy or who cannot tolerate radiopharmaceuticals may not benefit.
What this research studies
This grant supports a clinician-scientist at UW–Madison who aims to translate radiation-based strategies into CAR T cell therapy for pediatric solid tumors, especially neuroblastoma. The plan includes learning and mentorship across tumor immunology, radiochemistry, and dosimetry, with hands-on training and coursework to build a translational program. The work focuses on using low-dose targeted radionuclide therapy to make CAR T cells more effective at killing cancer cells in children. The goal is to move findings from the lab toward clinical application with proper oversight and collaboration. Training activities include seminars, conferences, and mentored research projects to advance both science and patient care.
Why it matters
Potential benefit: If successful, this approach could make CAR T cell therapy more effective for children with neuroblastoma.
How similar studies have gone: Prior work in combining targeted radiation with immunotherapy has shown promise, but this specific combination in pediatric neuroblastoma is still exploratory.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Sodji, Quaovi H — University of Wisconsin-Madison
- Study coordinator: Sodji, Quaovi H
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.